MIV Sees Promising Results From Stent Study

MIV Therapeutics received promising results from a trial of its VESTAsync polymer-free drug-eluting cardiovascular stent.

The study was a first-in-human, 12-month clinical follow-up involving 15 patients.

A nine-month follow-up using intravascular ultrasound and quantitative coronary angiography supported safety and efficacy data presented at the American College of Cardiology conference in March, MIV said.